Pharma Deals Review, Vol 2005, No 57 (2005)

Font Size:  Small  Medium  Large

Schering’s and Novartis’ New Co-Promotion Agreement for PTK/ZK

Business Review Editor

Abstract


Schering and Novartis formed a new co-promotion agreement for PTK787/ZK 222584 (PTK/ZK), a small molecule vascular endothelial growth factor (VEGF) receptor tyrosine kinases inhibitor for all oncology indications.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.